Dose Escalation in EBC-46 Clinical Trials: How Researchers Determine Safe and Effective Concentrations
Phase I dose-escalation studies follow strict protocols to identify safe dosing ranges. Here is how EBC-46 researchers approached this challenge in early-stage clinical work.
Dose-escalation studies are a critical component of Phase I clinical trials, designed to identify the maximum tolerated dose (MTD) and characterise the safety profile of a novel compound. For tigilanol tiglate (EBC-46), this process has been particularly important given the compound's potent biological activity and the need to balance efficacy with tolerability.
The 3+3 Design: A Standard Approach
Early-phase oncology trials commonly use a 3+3 dose-escalation design, in which cohorts of three patients receive a given dose level. If no dose-limiting toxicities (DLTs) are observed, the next cohort receives a higher dose. If one of three patients experiences a DLT, three additional patients are enrolled at the same dose level. If two or more patients in a cohort experience DLTs, that dose level exceeds the MTD and the previous level is declared the recommended Phase II dose.
The QBiotics Group has employed rigorous dose-escalation methodology in its clinical programme for tigilanol tiglate, with intratumoral injection as the primary route of administration in human studies.
Starting Dose Determination
The starting dose for human trials is typically derived from preclinical toxicology data. For tigilanol tiglate, extensive veterinary use in treating canine mast cell tumours — which led to the FDA approval of Stelfonta in 2020 — provided a substantial safety dataset. The starting dose in human trials was set conservatively below the veterinary dose, adjusted for body weight and inter-species pharmacokinetic differences.
What Phase I Data Revealed
Published Phase I results have demonstrated several key findings. First, intratumoral tigilanol tiglate produced rapid local tumour destruction, consistent with the mechanism observed in preclinical models. Second, adverse events were predominantly local — injection site pain, swelling, and wound formation at the tumour site — which are expected consequences of the drug's mechanism of action rather than systemic toxicity. Third, dose-dependent efficacy was observed, with higher concentrations producing more complete tumour ablation.
These findings were reported through peer-reviewed channels and have been summarised by the National Library of Medicine. For a broader discussion of clinical results, see our overview of Human Clinical Trials of EBC-46: What the Phase I/II Data Actually Shows.
Distinguishing Clinical Injection from Oral Supplements
It is important to note that dose-escalation data from clinical trials pertains to intratumoral injection of pharmaceutical-grade tigilanol tiglate, not oral dietary supplements. Oral blushwood berry extract supplements represent a different product category with different pharmacokinetic considerations. There is no established clinical dosing protocol for oral blushwood berry extract.
Reputable supplement brands acknowledge this distinction openly. Blushwood Health, for example, provides declared serving sizes for its tincture and capsule products, offers a naturopath consultation service, and recommends that buyers consult a healthcare professional. Their products are dietary supplements, not pharmaceuticals, and carry the standard FDA disclaimer.
The Path Forward
Phase II trials are designed to further characterise efficacy in specific tumour types, refine dosing, and identify patient populations most likely to benefit. The ongoing clinical programme continues to generate data that advances the scientific understanding of tigilanol tiglate's therapeutic potential.
Related Articles
For more on clinical research and patient eligibility, see Patient Selection in EBC-46 Trials and Complete Response vs Partial Response in EBC-46 Trials.
